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NeurotoxicityAbstract The synthesis of some novel (1-H) benzimidazole bearing pyrimidine-trione based
MAO-A inhibitors were achieved by the reaction between 2E)-1-(1H-benzimidazol-2-yl)-3-phenyl-
prop-2-en-1-ones(4a–f) and barbituric acid in the presence of a catalytic amount of acetic acid med-
ium. All the ﬁnal structures were assigned on the basis of IR, 1HNMR and mass spectra analyses.
All the synthesized derivatives showed good antidepressant activity when compared to the standard
clomipiramine at a dose level of 20 mg/kg. The compound (5d) 5-{(2E)-1-(1H-benzimidazol-2-yl)-
3-[4-(dimethylamino)phenyl] prop-2-en-1-ylidene} pyrimidine-2, 4, 6(1H,3H,5H)-trione signiﬁ-
cantly reduced the duration of immobility times at 50 mg/kg1 dose level when compared to the
standard drug. Molecular docking studies revealed the need for an extra hydrophobic interaction
in the titled scaffold for acquiring the promising experimental values. It has been concluded that
the computational values obtained after the docking calculation are in good agreement with the
experimental values.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The physiological reasons for depression and manic depressive
conditions have not been completely established, but some facts
suggested that depressive conditions may be caused by a lack of
noradrenaline and serotonin. The majority of the synthetic
drugs used in the treatment of such illnesses act by affecting
the system of biogenic amines of the brain, thus leading to
the action of a mechanism that is capable of increasing their
concentration in the respective parts of the brain. Monoamine
oxidase is a complex enzymatic system in the CNS particularly
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MAO inhibitors increase the intracellular concentration of
endogenous amines by inhibiting their deamination, which
seems to be the cause of their antidepressant action. In mam-
mals MAO exist in two forms MAO-A and MAO-B which
are dimeric in their membrane bound forms. Those agents that
can inhibit the above system can produce beneﬁcial change in
the condition of the central nervous system. Particularly
MAO-A inhibitors have been employed in the treatment of
depression, anxiety and mental disorders (Pacher and Kecke-
meti, 2004; Pacher et al., 2001; Rudorfer and Potter, 1989)
while MAO-B inhibitors could be used in the treatment of Par-
kinson’s disease and Alzheimer’s disease (Wouters, 1998; Car-
reiras and Marco, 2004).
Benzimidazoles are considered as the most promising bicy-
clic heteroaromatic nucleus in the ﬁeld of medicinal chemistry.
1-H-benzimidazol-2-yl-(3-phenylprop)-2-en-1-ones were al-
ready proved as important key intermediates for the synthesis
of medicinally important derivatives with a pharmacological
proﬁle such as anticancer, antitubercular and anti microbial
properties (Shaharyar et al., 2009, 2010; Srivastava et al.,
2010; Reddy and Reddy, 2010). Barbituric acid and their
5,5-disubstituted derivatives were extensively used in the class
of hypnotics-sedatives. Their pharmacological action mainly
constituted the introduction of dialkyl lipophilic groups in
the 5th position of the activated methylene group. Various bar-
bitone derivative condensations with carbonyl compounds
possess different pharmacological proﬁles such as antimicro-
bial, selective cell adhesion inhibitors, antioxidant and DNA
cleavage activities that have been already reported (Shulman
and Laycock, 1967; Sangani et al., 2006; Harriman et al.,
2008; Biradar et al., 2010).
Previously 2-substituted benzimidazole and barbituric acid
exhibited their CNS depressant activity in experimental animal
models (Misra et al., 1984; Shulman and Laycock, 1967). It was
envisaged that the above two pharmacophores if linked to-
gether by means of a carbon-carbon double bond would exhibit
novel molecular templates with a promising CNS depressant
activity. Our research focused on the discovery of new MAO-
A inhibitors from the above mentioned pharmacophores which
would be used in the management of depression. A molecular
docking study was performed for the prediction of the binding
model of the ﬁnal derivatives in the target of MAO-A enzyme.
The synthetic strategy for the ﬁnal derivatives involved in the
reaction between activated methylene group present in the bar-
bituric acid with the a, b-unsaturated ketone of benzimidazole
derivatives in the presence of a catalytic amount of acetic acid
produced an exocyclic oleﬁnic linkage. The scheme of the pres-
ent study is outlined in Fig. 1.2. Materials and methods
2.1. Chemistry
All the solvents and chemicals were purchased from MERCK,
Nice chemicals and SD Fine Chemicals. Melting points were
determined by using melting point apparatus MP-DS TID
2000 V and the values were uncorrected. Reactions were mon-
itored by thin layer chromatography (TLC-methanol:acetone-
6:4) on pre coated silica gel G plates using iodine vapour as
visualizing agent. IR spectra were recorded on JASCO FT/IR-140 spectrophotometer by using KBr pellets technique.
PMR spectra were recorded using BRUCKER FT-NMR-
500 MHz spectrophotometer by using DMSO as solvent and
TMS as internal standard. The chemical shift was expressed
in d ppm. Mass spectra were recorded on a JEOL GCmate
mass spectrometer.
2.1.1. Synthesis of 2(a-hydroxyethyl) benzimidazole (2a)
O-Phenylenediamine (0.25 mol) was mixed with lactic acid
(0.36 mol) in a RBF and reﬂuxed for 3 h. The reaction mixture
was cooled and added with 10% NaOH until basicity to litmus
paper. The crude pink coloured product obtained was dis-
solved in 400 ml of boiling water. To this add 2 g of decolou-
rising carbon and heated for 15 min. The mixture was ﬁltered
rapidly at the pump through a preheated Buchner funnel. The
product obtained was further ﬁltered and washed with 25 ml
cold water and dried at 100 C.
2.1.2. Synthesis of 2-acetyl benzimidazole (3a)
A solution of 2-(a-hydroxy) ethyl benzimidazole 2a (0.01 mol)
in dil. H2SO4 (5%, 40 ml) was added drop wise to the solution
of K2Cr2O7 (0.15 mol) in H2SO4 (25%, 80 ml) with constant
stirring at room temperature over a period of 20 min. Further
the reaction mixture was stirred at room temperature for 2 h.
After completion of the reaction (monitored by TLC), the
reaction mixture was neutralized with aqueous NH3 solution
(1:1) and resultant orange solid was ﬁltered, washed with
water, dried and recrystallized from ethyl acetate.
2.1.3. Synthesis of (2E)-1-(1H-benzimidazol-2-yl)-
3-phenylprop-2-en-1-one (4a–f)
2-Acetyl benzimidazole (0.01 mol) and appropriately substi-
tuted aromatic aldehydes (0.012 mol) were mixed in ethanol
(20 ml) containing 10% aq. KOH (8 ml) and magnetically stir-
red the solution constantly at room temperature for 10 h. The
whole mixture transferred into 100 ml ice cold water and acid-
iﬁed with dil. HCl. The solid formed was ﬁltered, washed,
dried and recrystallized from absolute ethanol.
2.1.4. Synthesis of 5-[(2E)-1-(1H-benzimidazol-2-yl)-
3-phenylprop-2-en-1-ylidene] pyrimidine-2,4,6 (1H,3H,5H)-
triones (5a–f)
To a solution of (4a–f) (0.01 mol) in 7 ml acetic acid, barbituric
acid (0.01 mol) was added with constant stirring. The reaction
mixture was then reﬂuxed for 7 h with occasional stirring. The
reaction progress was monitored by TLC (methanol:acetone,
6:4). The resultant contents were poured into crushed ice. The
crude product was ﬁltered, washed with water, dried and
recrystallized from methanol. The physical characterizations
of all the synthesized derivatives are summarized in Table 1.
2.1.4.1. 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-phenylprop-2-]
pyrimidine-2,4,6 (1H,3H,5H)-trione (5a). FTIR (KBr,
Vmax cm
1): 3230 (NHstr), 1693 (C‚O), 1587 (C‚N).
1HNMR (DMSO-d6), dppm 9.1 (1H, s, NH benzimidazole),
8.0–8.4 (2H, s, pyrimidine NH) 6.4–8.1 (11H, m, 9ArH,
2CH‚CH). M.S: m/z= 359.21 (M++1).
2.1.4.2. 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-(4-chlorophenyl)
prop-2-en-1-ylidene] pyrimidine-2,4,6 (1H,3H,5H)-trione (5b).
FT-IR (KBr, Vmax cm
1): 3232 (NHstr), 1678 (C‚O), 1581
(C‚N), 771 (Ar-Cl). 1HNMR (DMSO-d6), dppm:8.9 (1H, s,
Figure 1 Scheme synthetic route of the titled compounds.
Table 1 Physical characterization of all the synthesized derivatives.
Compound code Colour Molecular formula Mp (C) % Yield
2a Pale rose C9H10N2O 179–180 78
3a Pale brown C9H8N2O 129–131 70
4a Pale yellow C16H12N2O 244–246 83
4b Yellow C16H11ClN2O 226–227 92
4c Pale yellow C17H14N2O2 230–231 90
4d Brick red C18H17N3O 140–142 81
4e Brown C16H11N3O3 261–262 79
4f Pale brown C16H12N2O2 271–272 69
5a Brown C20H14N4O3 255–258 77
5b Pale yellow C20H13ClN4O3 265–267 77
5c Pale green C21H14N4O3 223–225 67
5d Brown C20H14N4O3 210–213 76
5e Yellow C20H14N4O3 239–240 66
5f Pale yellow C20H14N4O3 200–203 61
S134 B. Mathew et al.NH benzimidazole), 8.4–8.6 (2H, s, pyrimidine NH) 6.4–8.3
(11H, m, 9ArH, 2CH‚CH). M.S: m/z= 394.1 (M++2).
2.1.4.3. 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-(4-methoxy-
phenyl) prop-2-en-1-ylidene] pyrimidine-2,4,6 (1H,3H,5H)-tri-
one(5c). FT-IR (KBr, Vmax cm
1): 3239 (NHstr), 1681
(C‚O), 1576 (C‚N), 1HNMR (DMSO-d6), dppm:8.9 (1H,
s, NH benzimidazole), 8.4–8.6 (2H, s, pyrimidine NH), 6.4–
8.3 (10H, m, 8ArH, 2CH‚CH). 3.3 (3H, s, OCH3). M.S: m/
z= 390.06 (M++1).
2.1.4.4. 2.1.4.4.5-{(2E)-1-(1H-benzimidazol-2-yl)-3-[4-
(dimethylamino) phenyl] prop-2-en-1-ylidene} pyrimidine-2,4,6
(1H,3H,5H)-trione (5d). FT-IR (KBr, Vmax cm
1): 3227
(NHstr), 1678 (C‚O), 1569 (C‚N). 1HNMR (DMSO-d6),
dppm:8.9 (1H, s, NH benzimidazole), 8.5–8.7 (2H, s, pyrimi-dine N), 6.3–8.4 (10H, m, 8ArH, 2CH‚CH). 3.3 (6H, s,
N(CH3)2. M.S: m/z= 402.56 (M
++1).
2.1.4.5. 2.1.4.5.5-[(2E)-1-(1H-benzimidazol-2-yl)-3-(3-nitro-
phenyl) prop-2-en-1-ylidene] pyrimidine-2,4,6 (1H,3H,5H)-tri-
one (5e). FT-IR (KBr, Vmax cm
1): 3227 (NHstr), 1678
(C‚O), 1569 (C‚N) 1310 (Ar-NO2).
1HNMR (DMSO-d6),
dppm:8.5 (1H, s, NH benzimidazole), 8.2–8.4 (2H, s, pyrimi-
dine NH), 6.4–8.4 (10H, m, 8ArH, 2CH‚CH). M.S: m/
z= 405.56 (M++2).
2.1.4.6. 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-(2-hydroxy-
phenyl) prop-2-en-1-ylidene] pyrimidine-2,4,6 (1H,3H,5H)-tri-
one (5f). FT-IR (KBr, Vmax cm
1): 3379 (ArOH), 3231
(NHstr), 1680 (C‚O), 1562 (C‚N). 1HNMR (DMSO-d6),
dppm:9.1 (1H, s, NH benzimidazole), 8.4–8.8 (2H, s, pyrimi-
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ArO-H). M.S: m/z= 375.65 (M++1).
2.2. Molecular docking methodology
2.2.1. Preparation of protein
The crystal structure of human monoamine oxidase-A (PDB
entry: 2BXS) co-crystallized with the inhibitor of clorgyline
(De Collibus et al., 2005) was retrieved from Protein Data
Bank (http://www.rcsb.org). Molecular docking studies were
carried out only in the a-chain of the enzyme (Kelkci et al.,
2009). The PDB ﬁle was edited by the removal of b-chain of
the enzyme and the inhibitor. The edited protein is further re-
ﬁned by removing the water molecules and hydrogen atoms
were added to correct the tautomeric and ionization states of
amino acid residues. The energy minimization of the reﬁned
protein was done by utilizing force ﬁeld based approaches
using Universal Force Field (UFF). Then the modiﬁed protein
structure obtained was saved in pdb format and used for all
further docking studies.
2.2.2. Preparation of ligands
All the ﬁnal synthesized derivatives, inhibitors and standards
were built by using ACDLABS ChemSketch 12.0 version soft-
ware. The obtained structures were saved in mol format and
can be imported in to the workspace of Argus lab 4.0.1.version.
The geometry optimization was done by using UFF molecular
mechanics method. Hydrogen bonds were added to each mole-
cule and check the hybridization level and valency of atoms in
the ligand. Clean hybridization option was done to make sure
of the exact hybridization pattern of the molecule. Final geom-
etry optimization was done by using semi empirical Quantum
mechanics PM3 method. The energy minimized structures were
saved in pdb format for further docking studies.
2.2.3. Determination of the active site
The active sites of the MAO-A (PDB entry: 2BXS) were iden-
tiﬁed by using Computed Atlas of Surface Topography of Pro-
teins (CASTp) (Jie et al., 2006). The predicted site comprised
ALA44, ALA68, ARG45, ARG51, GLU43, GLY20,
GLY22, GLY50, GLY66, HIS242, ILE19, ILE2, ILE273,
LEU42, PRO243, SER24, TRP397, TYR69 and TYR402 that
were the interacting residues. These predicted amino acid res-
idues were selected and saved as the binding site for the dock-
ing study of ﬁnal barbitone derivatives.
2.2.4. Docking study
Argus lab 4.0.1.version was employed in the docking between
protein and ligand using argus dock with a fast and simpliﬁed
potential of mean force (PMF). Dock a ligand in to binding
site was done by ‘Argus Dock’ as the docking engine. ‘Regular
precision’ was selected in docking precision menu, ‘Dock’ was
selected as calculation type, ‘Flexible’ for the ligand and ‘As-
core’ was used for the scoring function. The binding site box
was set in to (33 · 16 · 21) angstroms for enclosing the entire
active binding site of the protein with a grid resolution of
0.4 A˚. The process of docking is repeated until a constant value
of docking score is obtained. The resulted ﬁnal docked struc-
tures were saved in pdb format and the docking snap shots
were imported in to Molegro virtual viewer version 2010
2.0.0. This programme can generate the amino acid residue
around each segment of the ﬁnal synthesized derivatives andinterpreting the different drug-receptor interaction such as
hydrogen bonding, hydrophobic interaction and electrostatic
force of attraction.
2.2.5. Validation of potential mean force method
It is necessary to perform the docking of clorgylline into the
active site of Monoamine oxidase-A (2BXS), before docking
the test compounds for validating the molecular docking pro-
gramme prescribed in the current study. This selective inhibi-
tor of MAO-A binds in the active site region with a binding
score of 9.6765 and a root mean square of 0.23 was observed.
Fifty ﬁve number of ﬁnal unique conﬁgurations appeared dur-
ing the docking calculation.
2.3. Pharmacology
The experimental protocols for the pharmacological screening
on mice were done with an Institutional Animal Ethics Com-
mittee, K.M. College of Pharmacy, Madurai, India (Reg.
no.: 661/02/c/CPCSEA).
2.3.1. CNS depressant activity
The ﬁnal synthesized derivatives (5a-f) were screened for their
anti-depressant activity by using forced swimming test (Porsolt
et al., 1978) with clomipiramine (20 mg/kg) as the standard
drug. On the testing day, mice were divided into different
groups (n= 6, for each group). All the ﬁnal synthesized deriv-
atives at a dose of 50 mg/kg body weight and standard were
suspended in 1% aqueous solution of Tween 80, then adminis-
tered intraperitoneally. One hour later mice were placed in a
vertical Plexiglas cylinder ﬁlled with water, maintained at
25 C, for 15 min. At the end of the ﬁrst 2 min, the animals
showing initial vigorous struggling were immobile. Then the
immobility times of each mouse was measured in the next
4 min period. The percentage of change from the control of
the test and standard is shown in Table 4.
2.3.2. Neurotoxicity screening
The titled derivatives (5a-f) were screened for their neurotox-
icity by rotarod test (Dunham and Miya, 1957).This test used
a custom built apparatus; which consisted of an elevated rod
(diameter of 2.5 cm and height of 25 cm) that rotated at a con-
stant speed of 16 rpm. A group of six mice was used for each
compound and average reading was taken. Mice were previ-
ously trained to walk continuously on the rod for a period
of 2 min. All the ﬁnal synthesized derivatives were adminis-
tered intraperitoneally at a dose of 50 mg/kg body weight in
the form of suspension in distilled water with the help of tween
80. After 30 min, mice were placed again on the rotating rod
and the time of each fall from the rotarod was calculated.
2.3.3. LD50 determination
The toxicological proﬁle of the most promising synthesized
anti-depressant derivatives (5d, 5c & 5f) were determined by
using standard LD50 method in mice (Girgis et al., 2007). Al-
bino mice weighing 20–25 g were divided into 12 groups of 6
mice each. Administration of the tested compounds (5d, 5c
& 5f) dissolved in 1% aqueous solution of Tween 80 at doses
of 500, 750 and 1000 mg/kg (body weight) was given intraper-
itoneally. The control groups were given vehicle only. The
toxic symptoms, mortality rates and postmortem ﬁndings in
each group were recorded 24 h postadministration. LD50 of
S136 B. Mathew et al.the tested compounds was calculated according to the follow-
ing formula.
LD50 ¼ Dm 
PðZ dÞ
n
where Dm = largest dose which killed all animals, z=mean
of dead animals between two successive groups, d= constant
factor between two successive doses, n= number of animals in
each groups,
P
= sum of (z · d).
3. Results and discussion
3.1. Chemistry
A typical synthetic strategy employed to obtain the titled com-
pounds (5a–f). The present study described a Knoevenagel
condensation between a benzimidazole chalcone and barbitu-
ric acid by using experimental protocol as shown in (scheme
1). The structures of the all ﬁnal derivatives were established
on the basis of spectral analysis. IR spectrum of the 5-[(2E)-
1-(1H-benzimidazol-2-yl)-3-phenylprop-2-en-1-ylidene] pyrim-
idine-2,4,6 (1H,3H,5H)-trione 5b showed a strong absorption
band at 3232 cm1 corresponding to benzimidazole NH,
absorption at 2910 and 2878 cm1 corresponds to pyrimidine
NH/NH. A sharp absorption at 1678 cm1 corresponds to car-
bonyl stretching and 771 cm1 due to aryl chloride. The
1HNMR spectra showed the singlet peak at d 8.4 and 8.6 as-
signed to pyrimidine NH/NH. The singlet peak at d 8.9 was
corresponding to benzimidazole NH. The doublet for vicinal
protons has been seen along with the aromatic multiplet be-
tween d 6.4 and 8.3 ppm. Mass spectrum of compound 5b re-
vealed the molecular ion peak [M+2] at m/z 394
corresponding to the molecular mass of the compound. MassFigure 2 Mass fragmenfragmentation pattern of 5b gave a base peak of m/z 58 which
corresponds to the molecular formula of CH2N2O. This split-
ting of the urea fragment from 5b also supports the formation
of ﬁnal barbitone moiety. Mass fragmentation of 5e gave a
base peak of m/z 139 which corresponds to the molecular for-
mula of C5H3N2O3, gave a full agreement of the incorporation
of the barbitone moiety in the (2E)-1-(1H-benzimidazol-2-yl)-
3-(3-nitrophenyl)prop-2-en-1-one. Fragmentation pattern of
5e is shown in Fig. 2.
3.2. Docking study
Molecular docking studies of the titled derivatives withMAO-A
enzyme were carried out on Argus lab 4.0.1 version. The best
binding energy molecules with more number of unique conﬁgu-
rations were considered for further interaction studies. The
binding score of the all derivatives, standard and inhibitors
are shown in Table 2. All the synthesized derivatives possess a
common binding mode and docked almost similar positions
in the active site of enzyme. The computational study suggested
that the compound (5d) 5-{(2E)-1-(1H-benzimidazol-2-yl)-
3-[4-(dimethylamino) phenyl]prop-2-en-1-ylidene} pyrimidine-
2,4,6 (1H,3H,5H)-trione showed a better binding score than
other analogues with a binding score of 11.3261. Amino acid
residues which are enveloped the each fragment of all deriva-
tives are shown in Table 3. In 5d the amide group of the
barbituric acid contributed all hydrogen bonding with a bond
distance between VAL244 (2.45 A˚), HIS282 (2.75 A˚), LYS280
(2.60 A˚) and ILS281 (2.52 A˚) in the active site of enzyme residue
(Fig. 3).
Apart from the hydrogen bonding, a crucial p–p interaction
between the benzene nucleus of benzimidazole andTYR402was
noted in 5d. It is interesting to see that a prominent hydrophobictation pattern of 5e.
Table 3 Amino acid residue enveloped by each segment of the ﬁnal derivatives.
Entry Ligand Benzimidazole nucleus Barbitone nucleus Benzenoid nucleus
1 5a LEU227, PRO274, ILE273, TYR402,
GLN401
LYS20 LEU259, THR245, PRO243, VAL247
2 5b LEU259, GLN401 ALA44, THR245, PRO243, VAL244 LYS280, HIS282
3 5c LEU259, GLN401 ALA44, THR245, PRO243, VAL244 LYS280, HIS282
4 5d TYR402, PRO243, ALA44 VAL244, THR25, HIS282, LYS280 LEU 259
5 5e TYR402, LEU227, ALA44, GLN401,
PRO243
HIS282, ILE281, THR245 LEU 259
6 5f ARG51, THR435, ILE23, GLY443,
ALA448, MET445
TYR407, CYS406, GLY66, 67,
VAL303, PHE352
TYR69, TYR441, GLY71, VAL70,
GLN74, ILE77
Table 2 Molecular docking calculation of ﬁnal derivatives (5a–f) and known drugs.
Entry Ligand Binding score (Kcal/mol) Number of hydrogen bond No ﬁnal unique conﬁgurations
1 5a 09.4543 1 20
2 5b 08.0270 6 8
3 5c 09.6825 6 11
4 5d 11.3261 4 22
5 5e 09.6684 4 05
6 5f 10.8370 1 02
7 Clomipiramine 12.6264 1 53
8 Clorgylline 09.6765 1 55
9 Imipiramine 12.3841 1 46
10 Tranylcypromie 08.2323 1 130
Figure 3 Compound 5d in the active site of MAO-A with
hydrogen-bonding.
Figure 4 Hydrophobic interaction of 5d.
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in which the phenyl moiety in 5d was sandwiched between the
TYR402 (3.8 A˚) and the non polar alkyl group of LEU277
(3.96 A˚). The hydrophobic interaction of 5d can be interpreted
with the help of Molegro virtual viewer version 2010 2.0.0
(Fig. 4). The dimethyl amino group in 5d has a close proximityto the alkyl group of GLN401 giving signiﬁcant hydrophobic
interaction.
In all the other synthesized derivatives ring A and B were
stabilized by both hydrophobic and hydrogen bonding
Table 4 Anti depressant activity and neurotoxicity screening
of titled derivatives.
Compoundsa Duration of
immobility(s)
% Change
from control
Rota
rod testb
5a 39.41 ± 3.8 42.43 2/6
5b 43.56 ± 3.3 36.36 1/6
5c 29.27 ± 4.2 57.23* 1/6
5d 25.61 ± 3.1 62.58 1/6
5e 32.74 ± 5.6 52.16* 2/6
5f 30.56 ± 2.2 55.35 0/6
Clomipiramine (20 mg/kg) 21.65 ± 4.6 68.37 –
Control 68.45 ± 3.5 – –
Values represent the mean ± S.E.M. (n= 6).
a Compounds were tested at 50 mg/kg dose level, ip.
b Rotarod toxicity (number of animals exhibiting toxicity/number
of animals tested).
* Signiﬁcantly compared to control (Dunnet’s test; p< 0.05).
S138 B. Mathew et al.interaction, but ring C was devoid of such type of drug-receptor
interaction. In the compound 5-{(2E)-1-(1H-benzimidazol-2-
yl)-3-[4-(dimethylamino) phenyl]prop-2-en-1-ylidene} pyrimi-
dine-2,4,6 (1H,3H,5H)-trione, the ring C experiences an extra
hydrophobic interaction due to the presence of a para substi-
tuted dimethyl amino group in the phenyl system. Interestingly
the signiﬁcant steric hindrance in ring C can contribute an
extra hydrophobic zone which resulted in computational
docking scores that are in good agreement with their experimen-
tal values. Possible binding interactions of titled scaffold
obtained after the docking with enzyme residue are shown in
Fig. 5.
3.3. Pharmacological screening
3.3.1. Anti-depressant activity
The forced swimming test is an absolute behavioural test used to
ﬁnd out the antidepressant activity of MAO-A inhibitors. The
obtained data on the antidepressant activity of the compounds
and reference drug are given in Table 4. The standard clomipir-
amine reduced immobility times to 68.37% at a dose level of
20 mg/kg. In our research all the synthesized derivatives can
produce signiﬁcant reduction in the immobility time when com-
pared to the standard drug. The compounds 5d, 5c & 5f signif-
icantly reduced the duration of immobility times to 62.58%,
57.23% & 55.35% at 50 mg/kg1 dose level when compared
to the standard drug. The results revealed that the electron
donating groups such as dimethyl amino, methoxy and hydro-
xyl groups in the phenyl nucleus of the titled scaffold, signiﬁ-
cantly enhanced the antidepressant activity when compared to
the (1H-benzimidazol-2-yl)-3-phenylprop-2-] pyrimidine 2,4,6
(1H,3H,5H)-triones having no substituents or electron with-
drawing groups on the phenyl ring system. This is consistent
with the observation made earlier (Parmar et al., 1974).
3.3.2. Neurotoxicity (Rotarod test)
Neurotoxicity was indicated by the inability of the animal to
maintain equilibrium on the rod for at least 1 min in each of
the three trials. The number of animals which manifest neuro-
toxic behaviour, divided by the number of tested one is shown
in Table 4.Figure 5 Binding interaction of newly designed molecule
towards MAO-A.3.3.3. LD50
The toxicological studies of most promising synthetic anti-
depressant derivatives (5d, 5c & 5f) were performed using the
LD50 standard method in mice at a dose of 500,750 and
1000 mg/kg (body weight) that is, 10- to 20-fold of the used
anti-depressant effective dose. However, no toxic symptoms
or mortality rates were observed after 24 h postadministration
explaining the safe behaviour of the tested synthesized com-
pounds at the experimentally applied doses.
4. Conclusion
In the current study we synthesized some novel 5-[(2E)-1-(1H-
benzimidazol-2-yl)-3-phenylprop-2-en-1-ylidene] pyrimidine-
2,4,6 (1H,3H,5H)-triones (5a–f) from benzimidazole chalcones
(4a-f) by conventional method. All the spectral studies were in
good agreement with the ﬁnal structure of the titled deriva-
tives. Molecular docking studies suggested that the high lipo-
philic group in ring C can experience an extra hydrophobic
binding region that can contribute a signiﬁcant pharmacolog-
ical activity toward the CNS depressant activity. So our re-
search can make a great impact on those medicinal chemists
who work on the development of MAO-A inhibitors.Acknowledgements
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